Is vaccination against transmissible spongiform encephalopathy feasible?

OIE Revue Scientifique et Technique

Volumn 26, Issue 1, 2007, Pages 243-251

  Wisniewski, T ^a   Chabalgoity, J A ^b   Goni, F ^a,b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF URUGUAY   (Uruguay)

Author keywords

Bovine spongiform encephalopathy; Chronic wasting disease; Conformational disorder; Mucosal vaccine; Prion; Salmonella; Transmissible spongiform encephalopathy; Variant Creutzfeldt Jakob disease

Indexed keywords

ANIMALIA; BOVINAE; SALMONELLA;

EID: 34447630226     PISSN: 02531933     EISSN: 16080645     Source Type: Journal    
DOI: 10.20506/rst.26.1.1739     Document Type: Article

References (63)

1. Angers R.C., Browning S.R., Seward T.S., Sigurdson C.J., Miller M.W, Hoover E.A. & Telling G.C. (2006). - Prions in skeletal muscles of deer with chronic wasting disease. Science, 311, 1117.
2. Asuni A., Boutajangout A., Scholtzova H., Knudsen E., Li Y., Quartermain D., Frangione B., Wisniewski T. & Sigurdsson E.M. (2006). - Aß derivative vaccination in alum adjuvant prevents amyloid deposition and does not cause brain microhemorrhages in Alzheimer's model mice. Eur. J. Neurosci., 24, 2530-2542.
3. Aucouturier P., Kascsak R.J., Frangione B. & Wisniewski T. (1999). - Biochemical and conformational variability of human prion strains in sporadic Creutzfeldt-Jakob disease. Neurosci. Lett., 274, 33-36.
4. Aucouturier P., Carp R.I., Carnaud C. & Wisniewski T. (2000). - Prion diseases and the immune system. Clin. Immunol., 96, 79-85.
5. Aucouturier P., Geissmann F., Damotte D., Saborio G.P., Meeker H.C., Kascsak R., Kascsak R., Carp R.I. & Wisniewski T. (2001). - Infected dendritic cells are sufficient for prion transmission to the CNS in mouse scrapie. J. clin. Invest., 108, 703-708.
6. Bard F., Cannon C., Barbour R., Burke R.L., Games D., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., Kholodenko D., Lee M., Lieberburg I., Motter R., Nguyen M., Soriano F., Vasquez N., Weiss K., Welch B., Seubert P., Schenk D. & Yednock T. (2000). - Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med., 6, 916-919.
7. Belay E.D., Maddox R.A., Williams E.S., Miller M.W., Gambetti P. & Schonberger L.B. (2004). - Chronic wasting disease and potential transmission to humans. Emerg. infect. Dis., 10, 977-984.
8. Bradley R., Collee J.G. & Liberski PP (2006). - Variant CJD (vCJD) and bovine spongiform encephalopathy (BSE): 10 and 20 years on: Part 1. Folia neurapathol, 44 (2), 93-101.
9. Brown D.R., Qin K., Herms J.W., Madlung A., Manson J., Strome R., Fraser P.E., Kruck T., von Bohlen A., Schulz-Schaeffer W., Giese A., Westaway D. & Kretzschmar H. (1997). - The cellular prion protein binds copper in vivo. Nature, 390, 684-687.
10. Brown K.L., Ritchie D.L., McBride PA. & Bruce M.E. (2000). - Detection of PrP in extraneural tissues. Microsc. Res. Tech., 50, 40-45.
11. Brown P., Brandel J.P, Preese M. & Sato T. (2006). -latrogenic Creutzfeldt-Jakob disease: the waning of an era. Neurology, 67, 389-393.
12. Bueler H., Fischer M., Lang Y., Bluethmann H., Lipp H.P., DeArmond S.J., Prusiner S.B., Aguet M. & Weismann J.S. (1992). - Normal development and behaviour of mice lacking the neuronal cell-surface PrP protein. Nature, 356, 577-582.
13. Chabalgoity J.A., Moreno M., Carol H., Dougan G. & Hormaeche C.E. (2000). - Salmonella typhimurium as a basis for a live oral Echinococcus granulosus vaccine. Vaccine, 19, 460-469.
14. Collinge J., Whittington M.A., Sidle K.C., Smith C.J., Palmer M.S., Clarke A.R. & Jefferys J.G.R. (1994). - Prion protein is necessary for normal synaptic function. Nature, 370, 295-297.
15. Collinge J., Whitfield J., McKintosh E., Beck J., Mead S., Thomas D.J. & Alpers M.R (2006). - Kuru in the 21st century: an acquired human prion disease with very long incubation periods. Lancet, 367, 2068-2074.
16. Enari M., Flechsig E. & Weissmann C. (2001). - Scrapie prion protein accumulation by scrapie-infected neuroblastoma cells abrogated by exposure to a prion protein antibody. Proc. natl Acad. Sci. USA, 98, 9295-9299.
17. Ferrer I., Boada R.M., Sanchez Guerra M.L., Rey M.J. & Costa-Jussa F. (2004). - Neuropathology and pathogenesis of encephalitis following amyloid-beta immunisation in Alzheimer's disease. Brain Pathol., 14, 11-20.
18. Gilman S., Koller M., Black R.S., Jenkins L., Griffith S.G., Fox N.C., Eisner L., Kirby L., Boada Rovira M., Forette F. & Orgogozo J.M. (2005). - Clinical effects of Aβ immunisation (AN1792) in patients with AD in an interrupted trial. Neurology, 64, 1553-1562.
19. Hock C., Konietzko U., Straffer J.R., Tracy J., Signorell A., Muller-Tillmanns B., Lemke U., Henke K., Moritz E., Garcia E., Axel Wollmar M., Umbricht D., de Quervain D.J.F., Hofmann M., Maddalena A., Papassotiropoulos A. & Nitsch R.M. (2003). - Antibodies against β-amyloid slow cognitive decline in Alzheimer' disease. Neuron, 38, 547-554.
20. Janus C., Pearson J., McLaurin J., Mathews P.M., Jiang Y., Schmidt S.D., Chishti M.A., Home P., Heslin D., French J., Mount H.T., Nixon R.A., Mercken M., Bergeron C., Fraser P.E., George-Hyslop P. & Westaway D. (2000). - Aβ peptide immunisation reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature, 408, 979-982.
21. Jendroska K., Heinzel F.P., Torchia M., Stowring L.E., Kretzschmar H., Kon A., Stern A., Prusiner S.B. & DeArmond S.J. (1991). - Proteinase-resistant prion protein accumulation in Syrian hamster brain correlates with regional pathology and scrapie infectivity. Neurology, 41, 1482-1490.
22. Jimenez-Huete A., Lievens P.M.J., Vidal R., Piccardo P., Ghetti B., Tagliavini F., Frangione B. & Prelli F. (1998). - Endogenous proteolytic cleavage of normal and disease-associated isoforms of the human prion protein in neural and non-neural tissues. Am. J. Pathol., 153, 1561-1572.
23. Kirkpatrick B.D., McKenzie R., O'Neill J.P., Larsson C.J., Bourgeois A.L., Shimko J., Bentley M., Makin J., Chatfield S., Hindle Z., Fidler C., Robinson B.E., Ventrone C.H., Bansal N., Carpenter C.M., Kutzko D., Hamlet S., Lapointe C. & Taylor D.N. (2006). - Evaluation of Salmonella enterico serovar Typhi (Ty2 aroC-ssaV-) M01ZH09, with a defined mutation in the Salmonella pathogenicity island 2, as a live, oral typhoid vaccine in human volunteers. Vaccine, 24, 116-123.
24. Kretzschmar H., Prusiner S.B., Stowring L.E. & DeArmond S.J. (1986). - Scrapie prion protein are synthesized in neurons. Am. J. Pathol., 122, 1-5.
25. Liberski P.P., Guiroy D.C., Williams E.S., Walis A. & Budka H. (2001). - Deposition patterns of disease-associated prion protein in captive mule deer brains with chronic wasting disease. Acta neuropathol., 102, 496-500.
26. Mabbott N.A. & MacPherson G.G. (2006). - Prions and their lethal journey to the brain. Nat. Rev. Microbiol., 4, 201-211.
27. Manuelidis L. (1998). - Vaccination with an attenuated Creutzfeldt-Jakob disease strain prevents expression of a virulent agent. Proc. natl Acad. Sci. USA, 95, 2520-2525.
28. Masliah E., Hansen L., Adame A., Crews L., Bard F., Lee C., Seubert P., Games D., Kirby L. & Schenk D. (2005). - Aβ vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology, 64, 129-131.
29. Mastroeni P., Chabalgoity J.A., Dunstan S.J., Maskell D.J. & Dougan G. (2001). - Salmonella: immune responses and vaccines. Vet. J., 161, 132-164.
30. Mathiason C.K., Powers J.G., Dahmes S.J., Osborn D.A., Miller K.V., Warren R.J., Mason G.L., Hays S.A., Hayes-Klug J., Seelig D.M., Wild M.A., Wolfe L.L., Spraker T.R., Miller M.W, Sigurdson C.J., Telling G.C. & Hoover E.A. (2006). - Infectious prions in the saliva and blood of deer with chronic wasting disease. Science, 314, 133-136.
31. Morgan D. (2006). - Immunotherapy for Alzheimer's disease. J. Alzheimer's Dis., 9, 425-432.
32. Morgan D., Diamond D.M., Gottschall P.E., Ugen K.E., Dickey C., Hardy J., Duff K., Jantzen P., DiCarlo G., Wilcock D., Connor K., Hatcher J., Hope C., Gordon M. & Arendash G.W. (2001). - Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature, 408, 982-985.
33. Nicoll J.A., Wilkinson D., Holmes C., Steart P., Markham H. & Weller R.O. (2005). - Neuropathology of human Alzheimer disease after immunisation with amyloid-beta peptide: a case report. Nat. Med., 9, 448-452.
34. Pankiewicz J., Prelli F., Sy M.S., Kascsak R.J., Kascsak R.B., Spinner D.S., Carp R.I., Meeker H.C., Sadowski M. & Wisniewski T. (2006). - Clearance and prevention of prion infection in cell culture by anti-PrP antibodies. Eur J. Neurosd., 24, 2635-2647.
35. Peretz D., Williamson R.A., Kaneko K., Vergara J., Ledere E., Schmitt-Ulms G., Mehlhorn I.R., Legname G., Wormald M.R., Rudd P.M., Dwek R.A., Burton D.R. & Prusiner S.B. (2001). - Antibodies inhibit prion propagation and clear cell cultures of prion infectivity. Nature, 412, 739-743.
36. Polymenidou M., Heppner F.L., Pellicioli E.C., Urich E., Miele G., Braun N., Wopfner F., Schatzl H.M., Becher B. & Aguzzi A. (2004). - Humoral immune response to native eukaryotic prion protein correlates with anti-prion protection. Proc. natlAcad. Sci. USA, 101, 14670-14676.
37. Prusiner S.B. (1982). - Novel proteinaceous infectious particles cause scrapie. Science, 216, 136-144.
38. Prusiner S.B, (2001). - Neurodegenerative diseases and prions. N. Engl. J. Med., 344, 1516-1526.
39. Qin K., Yang D.S., Yang Y., Chishti M.A., Meng L.J., Kretzschmar H.A., Yip C.M., Fraser P.E. & Westaway D. (2000). - Copper(II)-induced conformational changes and protease resistance in recombinant and cellular PrP. Effect of protein age and deamidation. J. biol. Chem., 275, 19121-19131.
40. Qin K., Yang Y., Mastrangelo P. & Westaway D. (2002). - Mapping Cu(II) binding sites in prion proteins by diethyl pyrocarbonate modification and matrix-assisted laser desorption ionisation-time of flight (MALDI-TOF) mass spectrometric footprinting. J. biol. Chem., 277, 1981-1990.
41. Raymond G.J., Bossers A., Raymond L.D., O'Rourke K.I., McHolland L.E., Bryant P.K. III, Miller M.W., Williams E.S., Smits M. & Caughey B, (2000). - Evidence of a molecular barrier limiting susceptibility of humans, cattle and sheep to chronic wasting disease. EMBO J., 19, 4425-4430.
42. Sadowski M., Verma A. & Wisniewski T. (2004). - Prion diseases. In Neurology in clinical practice, 4th Ed. (W. Bradley, ed.). Chapter 59G, 1613-1630.
43. Sadowski M. & Wisniewski T. (2004). - Vaccines for conformational disorders. Expert Rev. Vaccines, 3, 89-100.
44. Sassoon J., Sadowski M., Wisniewski T. & Brown D.R. (2005). - Therapeutics and prion disease: can immunisation or drugs be effective? Mini Revs, med. Chem., 5, 361-366.
45. Sigurdsson E.M., Scholtzova H., Mehta P., Frangione B. & Wisniewski T. (2001). - Immunisation with a non-toxic/non-fibrillar amyloid-β homologous peptide reduces Alzheimer's disease associated pathology in transgenic mice. Am, J. Pathol., 159, 439-447.
46. Sigurdsson E.M., Brown D.R., Daniels M., Kascsak R.J., Kascsak R., Carp R.I., Meeker H.C., Frangione B. & Wisniewski T. (2002). - Vaccination delays the onset of prion disease in mice. Am. J. Pathol., 161, 13-17.
47. Sigurdsson E.M., Sy M.S., Li R., Scholtzova H., Kascsak R.J., Kascsak R., Carp R.I., Meeker H.C., Frangione B. & Wisniewski T. (2003). - Anti-PrP antibodies for prophylaxis following prion exposure in mice. Neurosci. Lett., 336, 185-187.
48. Sigurdsson E.M., Brown D.R., Alim M.A., Scholtzova H., Carp R.I., Meeker H.C., Prelli F., Frangione B. & Wisniewski T. (2003). - Copper chelation delays the onset of prion disease.;, biol. Chem., 278, 46199-46202.
49. Sigurdsson E.M., Knudsen E.L., Asuni A., Sage D., Goni F., Quartermain D., Frangione B. & Wisniewski T. (2004). - An attenuated immune response is sufficient to enhance cognition in an Alzheimer's disease mouse model immunized with amyloid-β derivatives. J Neurosci., 24, 6277-6282.
50. Sigurdsson E.M. & Wisniewski T. (2005). - Promising developments in prion immunotherapy. Expert Rev. Vaccines, 4, 607-610.
51. Smith M.A., Harris P.L., Sayre L.M. & Perry G. (1997). - Iron accumulation in Alzheimer disease is a source of redox-generating free radicals. Proc. natl Acad. Sci. USA, 94, 9866-9868.
52. Smith M.A., Hirai K. Hsiao K., Pappolla M., Harris P.L., Siedlak S.L., Tabaton M. & Perry G. (1998). - Amyloid beta deposition in Alzheimer transgenic mice is associated with oxidative stress. J. Neurochem., 70, 2212-2215.
53. Tacket C.O., Sztein M.B., Wasserman S.S., Losonsky G., Kotloff K.L., Wyant T.L., Nataro J.P, Edelman R., Perry J., Bedford P., Brown D., Chatfield S., Dougan G. & Levine M.M. (2000). - Phase 2 clinical trial of attenuated Salmonella enterica serovar typhi oral live vector vaccine CVD 908-htrA in US volunteers. Infect. Immun., 68, 1196-1201.
54. Tamguney G., Giles K., Bouzamondo-Bernstein E., Bosque P.J., Miller M.W, Safar J., DeArmond S.J. & Prusiner S.B. (2006). - Transmission of elk and deer prions to transgenic mice J. Virol., 80, 9104-9114.
55. Tobler I., Gaus S.E., Deboer T., Achermann P., Fischer M., Rülicke T., Moser M., Oesch B., McBride PA. & Manson J.C. (1996). - Altered circadian activity rhythms and sleep in mice devoid of prion protein. Nature, 380, 639-642.
56. Trevitt C.R. & Collinge J. (2006). - A systematic review of prion therapeutics in experimental models. Brain, 129, 2241-2265.
57. Villarreal-Ramos B., Manser J., Collins R.A., Dougan G., Chatfield S.N. & Howard C.J. (1998). - Immune responses in calves immunised orally or subcutaneously with a live Salmonella typhimurium aro vaccine. Vaccine, 16, 45-54.
58. Weiner H.L. & Frenkel D. (2006). - Immunology and immunotherapy of Alzheimer's disease. Nat. Rev. Immunol., 6, 404-416.
59. White A.R., Enever P., Tayebl M., Mushens R., Linehan J., Brandner S., Anstee D., Collinge J. & Hawke S. (2003). - Monoclonal antibodies inhibit prion replication and delay the development of prion disease. Nature, 422, 80-83.
60. Will R.G., Ironside J., Zeidler M., Cousens S.N., Estibeiro K., Alperovitch A., Poser S., Pocchiari M., Hofman A. & Smith PG. (1996). - A new variant of Creutzfeldt-Jacob disease in the UK. Lancet, 347, 921-925.
61. Williams E.S. (2005). - Chronic wasting disease. Vet. Pathol., 42, 530-549.
62. Wisniewski T. (2005). - Commentary on 'Clinical effects of Aβ immunisation (AN1792) in patients with AD in an interrupted trial. Nat. clin. Pract. Neurol., 64, 1553-1562.
63. Wisniewski T. & Frangione B. (2005). - Immunological and anti-chaperone therapeutic approaches for Alzheimer's disease. Brain Pathol., 15, 72-77.